{{Drugbox
| Verifiedfields = 
| Watchedfields = 
| verifiedrevid = 
| IUPAC_name = 6-(4-methylpiperazin-1-yl)-11''H''-benzo[''c''][1]benzazepine
| image = 
| width = 

<!--Clinical data-->
| tradename = Hypnodine, Pipnodine
| pregnancy_AU = <!-- A / B1 / B2 / B3 / C / D / X -->
| pregnancy_US = <!-- A / B            / C / D / X -->
| pregnancy_category = 
| legal_AU = <!-- Unscheduled / S2 / S3 / S4 / S5 / S6 / S7 / S8 / S9 -->
| legal_CA = 
| legal_UK = 
| legal_US = 
| legal_status = 
| routes_of_administration = 

<!--Pharmacokinetic data-->
| bioavailability = 
| protein_bound = 
| metabolism = 
| elimination_half-life = 
| excretion = 

<!-- Identifiers -->
| CAS_number_Ref = 
| CAS_number = 1977-11-3
| CAS_supplemental = 
| class = 
| ATC_prefix = 
| ATC_suffix = 
| ATC_supplemental = 
| PubChem = 16106
| IUPHAR_ligand = 
| DrugBank_Ref = 
| DrugBank = 
| ChemSpiderID_Ref = 
| ChemSpiderID = 15291
| UNII = 4N8UJJ27IM
| KEGG = D01438
| ChEBI = 31983
| ChEMBL = 340801
| synonyms = AW-14233; HF-2333; MP-11; PLP 100-127; 6-(4-Methyl-1-piperazinyl)morphanthridine

<!--Chemical data-->
| C=19 | H=21 | N=3
| molecular_weight = 291.398 g/mol
| SMILES = CN1CCN(CC1)C2=NC3=CC=CC=C3CC4=CC=CC=C42
| StdInChI_Ref = 
| StdInChI = 1S/C19H21N3/c1-21-10-12-22(13-11-21)19-17-8-4-2-6-15(17)14-16-7-3-5-9-18(16)20-19/h2-9H,10-14H2,1H3
| StdInChIKey_Ref = 
| StdInChIKey = PWRPUAKXMQAFCJ-UHFFFAOYSA-N
}}

'''Perlapine''', sold under the brand names '''Hypnodine''' and '''Pipnodine''', is a [[hypnotic]] and [[sedative]] of the [[tricyclic compound|tricyclic]] group which is marketed in [[Japan]].<ref name="IndexNominum2000">{{cite book|title=Index Nominum 2000: International Drug Directory|url=https://books.google.com/books?id=5GpcTQD_L2oC&pg=PA811|year=2000|publisher=Taylor & Francis|isbn=978-3-88763-075-1|pages=811–}}</ref> It acts primarily as a [[potency (pharmacology)|potent]] [[antihistamine]],<ref name="Lajtha2013">{{cite book|author=Abel Lajtha|title=Alterations of Metabolites in the Nervous System|url=https://books.google.com/books?id=dYnSBwAAQBAJ&pg=PA352|date=11 November 2013|publisher=Springer Science & Business Media|isbn=978-1-4757-6740-7|pages=352–}}</ref> and also has [[anticholinergic]],<ref name="Lajtha2013" /> [[antiserotonergic]],<ref name="Elsevier1996">{{cite book|title=Progress in Medicinal Chemistry|url=https://books.google.com/books?id=SDaZ4qcemf8C&pg=PA226|date=24 April 1996|publisher=Elsevier|isbn=978-0-08-086281-1|pages=226–}}</ref> [[antiadrenergic]], and some [[antidopaminergic]] activity.<ref name="Elsevier1996" /><ref name="Hathway2007">{{cite book|author=D E Hathway|title=Foreign Compound Metabolism in Mammals|url=https://books.google.com/books?id=UHAoDwAAQBAJ&pg=PA302|date=31 October 2007|publisher=Royal Society of Chemistry|isbn=978-1-84755-608-0|pages=302–}}</ref><ref name="Publishers1995">{{cite book|author=Bentham Science Publishers|title=Current Medicinal Chemistry|url=https://books.google.com/books?id=eMw2LsjQ5PQC&pg=PA489|date=April 1995|publisher=Bentham Science Publishers|pages=489–}}</ref><ref name="Barnes2013">{{cite book|author=Thomas R.E. Barnes|title=Antipsychotic Drugs and Their Side-Effects|url=https://books.google.com/books?id=IT2OAgAAQBAJ&pg=PA34|date=22 October 2013|publisher=Elsevier Science|isbn=978-1-4832-8810-9|pages=28,34}}</ref> The drug has relatively weak [[affinity (pharmacology)|affinity]] for the [[dopamine]] [[D2 receptor|D<sub>2</sub> receptor]] ({{abbrlink|IC<sub>50</sub>|Half-maximal inhibitory concentration}} = 1,803&nbsp;nM) and, in accordance, is said to be ineffective as an [[antipsychotic]].<ref name="Barnes2013" /><ref name="Neuropsychopharmacology1978">{{cite book|author=American College of Neuropsychopharmacology|title=Psychopharmacology: a generation of progress|url=https://books.google.com/books?id=c-RsAAAAMAAJ|year=1978|publisher=Raven Press|isbn=978-0-89004-191-8|page=514}}</ref> However, it retains higher affinity for the dopamine [[D1 receptor|D<sub>1</sub> receptor]] ({{abbr|IC<sub>50</sub>|Half-maximal inhibitory concentration}} = 198&nbsp;nM).<ref name="Barnes2013" /> Its {{abbr|IC<sub>50</sub>|Half-maximal inhibitory concentration}} values are 19&nbsp;nM for the [[alpha-1 adrenergic receptor|α<sub>1</sub>-adrenergic receptor]], 4,945&nbsp;nM for the [[alpha-2 adrenergic receptor|α<sub>2</sub>-adrenergic recpetor]], and 70&nbsp;nM for the [[serotonin]] [[5-HT2A receptor|5-HT<sub>2A</sub> receptor]].<ref name="Barnes2013" /> Perlapine is closely related to [[clotiapine]], [[clozapine]], [[fluperlapine]], [[loxapine]], and [[tilozepine]].<ref name="Barnes2013" />

==References==
{{Reflist|2}}


{{Antihistamines}}
{{Sedatives}}
{{Navboxes
| title = [[Pharmacodynamics]]
| titlestyle = background:#ccccff
| list1 = 
{{Adrenergic receptor modulators}}
{{Dopamine receptor modulators}}
{{Histamine receptor modulators}}
{{Muscarinic acetylcholine receptor modulators}}
{{Serotonin receptor modulators}}
}}
{{Tricyclics}}

[[Category:Alpha-1 blockers]]
[[Category:Dibenzodiazepines]]
[[Category:Dopamine antagonists]]
[[Category:H1 receptor antagonists]]
[[Category:Muscarinic antagonists]]
[[Category:Piperazines]]
[[Category:Serotonin antagonists]]


{{Nervous-system-drug-stub}}